Thank you very much, Mr. Chair.
Thanks to the witnesses for being here today.
Hopefully, we'll have time to get back to Ms. Priddy, because she's always very enlightening.
My first question is to Ms. Bruce.
First of all, I'd like to make a quick comment. Following the last meeting, we had a number of comments that the CDR represents a barrier to patient access. The avenue that I'm taking to this study is this. What's going to enhance patient access to pharmaceuticals?
There were comments made that the CDR represents a barrier to access. It provides unnecessary duplication as the provinces do their own reviews. There are significant delays. There's a lack of transparency, a real lack of accountability, and we're learning today that no consistency exists in the process.
Ms. Bruce, if the CDR is working as well as you say it is, why does it have so many critics?